Yu Yao

4.5k total citations · 2 hit papers
104 papers, 2.3k citations indexed

About

Yu Yao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yu Yao has authored 104 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Yu Yao's work include Lung Cancer Treatments and Mutations (18 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Lung Cancer Research Studies (11 papers). Yu Yao is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Lung Cancer Research Studies (11 papers). Yu Yao collaborates with scholars based in China, United States and Spain. Yu Yao's co-authors include Amer Assal, Xingxing Zang, Eszter Lázár‐Molnár, Kim C. Ohaegbulam, Yi Shao, Junmin Qian, Aili Suo, Tao Tian, Wanggang Zhang and Xuan Liang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yu Yao

93 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

2014 654 citations Yu Yao et al. profile →
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 201 citations Yongliang Zhang, Yu Yao et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yu Yao China	23	909	701	462	452	445	104	2.3k
Bangshun He China	23	952 1.0×	1.0k 1.5×	683 1.5×	397 0.9×	426 1.0×	92	2.6k
Aina He China	32	891 1.0×	900 1.3×	405 0.9×	749 1.7×	485 1.1×	83	2.8k
Lu Cao China	25	609 0.7×	720 1.0×	526 1.1×	295 0.7×	186 0.4×	157	2.4k
Yuanyuan Jiang China	30	590 0.6×	1.4k 2.0×	494 1.1×	544 1.2×	361 0.8×	191	3.0k
Yong Fang China	29	732 0.8×	1.3k 1.8×	365 0.8×	330 0.7×	212 0.5×	128	2.5k
Zhi Yang China	30	832 0.9×	1.6k 2.4×	891 1.9×	330 0.7×	306 0.7×	113	3.0k
Teresa Puig Spain	32	676 0.7×	1.0k 1.5×	618 1.3×	404 0.9×	239 0.5×	115	3.1k
Bing Xu China	31	693 0.8×	1.5k 2.2×	482 1.0×	295 0.7×	452 1.0×	192	3.1k
Ying Zhu China	34	754 0.8×	1.5k 2.2×	897 1.9×	379 0.8×	898 2.0×	145	3.4k
Cristiana Tănase Romania	28	468 0.5×	767 1.1×	352 0.8×	198 0.4×	328 0.7×	93	2.6k

Countries citing papers authored by Yu Yao

Since Specialization

Citations

This map shows the geographic impact of Yu Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Yao more than expected).

Fields of papers citing papers by Yu Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Yao. The network helps show where Yu Yao may publish in the future.

Co-authorship network of co-authors of Yu Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Yao. A scholar is included among the top collaborators of Yu Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Yao. Yu Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Na, Xiaoqiang Zheng, Jin Yan, et al.. (2024). Reversing MET‐Mediated Resistance in Oncogene‐Driven NSCLC by MET‐Activated Wnt Condensative Prodrug. Advanced Science. 11(30). e2400603–e2400603. 5 indexed citations

Valdiviezo, Natalia, Pasi A. Jänne, Ying Cheng, et al.. (2024). MA12.04 FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC. Journal of Thoracic Oncology. 19(10). S102–S102. 5 indexed citations

Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248. 5 indexed citations

Liu, Haixia, et al.. (2024). Social support and depressive symptoms among migrant elderly following children: the chain mediating role of resilience and loneliness. BMC Psychiatry. 24(1). 898–898.

Zhao, Ni, Aimin Jiang, Xiao Shang, et al.. (2023). Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels. Journal of Immunotherapy. 46(8). 310–322. 3 indexed citations

Jiang, Aimin, Yimeng Li, Ni Zhao, et al.. (2023). A novel risk classifier to predict the in-hospital death risk of nosocomial infections in elderly cancer patients. Frontiers in Cellular and Infection Microbiology. 13. 1179958–1179958. 2 indexed citations

Wang, Ruoxuan, Aimin Jiang, Rui Zhang, et al.. (2023). Establishment of a risk classifier to predict the in-hospital death risk of nosocomial fungal infections in cancer patients. BMC Infectious Diseases. 23(1). 472–472. 2 indexed citations

Chen, Xue, Aimin Jiang, Rui Zhang, et al.. (2022). Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. Frontiers in Cardiovascular Medicine. 9. 882167–882167. 22 indexed citations

Jiang, Aimin, Haoran Zheng, Na Liu, et al.. (2021). Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis. Cancer Control. 28. 2895468629–2895468629. 5 indexed citations

10.

Jiang, Aimin, Na Liu, Rui Zhao, et al.. (2021). Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study. Cancer Control. 28. 2895469276–2895469276. 7 indexed citations

11.

Zhang, Jinyao, Yan Wang, Ziling Liu, et al.. (2021). Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases. Thoracic Cancer. 12(24). 3407–3415. 23 indexed citations

12.

Zhang, Yongliang, Yu Yao, Yaping Xu, et al.. (2021). Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nature Communications. 12(1). 11–11. 201 indexed citations breakdown →

13.

Wu, Jiayi, Shao‐Jie Gao, Shuang Zhang, et al.. (2021). Perioperative risk factors for recovery room delirium after elective non-cardiovascular surgery under general anaesthesia. SHILAP Revista de lepidopterología. 10(1). 3–3. 15 indexed citations

14.

Fu, Xiao, Zhiyan Liu, Mengjie Liu, et al.. (2020). <p>PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer</p>. Cancer Management and Research. Volume 12. 10939–10948. 10 indexed citations

15.

Jia, Xiaohui, Panpan Jiang, Hongxia Xu, et al.. (2020). The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. Journal of Experimental & Clinical Cancer Research. 39(1). 284–284. 82 indexed citations

16.

Jiang, Aimin, Xin Shi, Na Liu, et al.. (2020). Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China. BMC Infectious Diseases. 20(1). 452–452. 30 indexed citations

17.

Fu, Xiao, Tao Tian, Zhiping Ruan, et al.. (2019). EP1.12-22 The Expression and Prognostic Roles of PD-L1, PAPR1 and DLL3 in Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S1024–S1025. 1 indexed citations

18.

Shao, Yi, Yu Yao, Rongrong Zong, et al.. (2016). Erlotinib has tumor inhibitory effect in human retinoblastoma cells. Biomedicine & Pharmacotherapy. 85. 479–485. 9 indexed citations

19.

Sun, Yu, Wei Zhao, Chunpeng Zhu, et al.. (2015). Effect of deferoxamine mesylate on occupied volume and 90 days prognosis in patients after intracerebral hemorrhage. Chinese Journal of Neuromedicine. 14(10). 1023–1026. 1 indexed citations

20.

Zheng, Qi, et al.. (2013). CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line. World Journal of Surgical Oncology. 11(1). 5–5. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact